ACAT1 and neoplasm: As an ACAT-1 inhibitor, AVA increases membrane cholesterol levels, thereby enhancing T cell receptor signaling and cytokine secretion to boost T-cell function, and downregulates the expression of the cholesterol biosynthesis transcription factor SREBP2 and the migration-associated protein integrin αV, thereby suppressing tumor invasion.